Alphabet and Merck Group could exit the immunological and inflammatory disease therapy developer in an offering with an $86.3m placeholder target.
Vera Therapeutics, a US-based immunological and inflammatory disease therapy developer backed by internet technology group Alphabet and pharmaceutical firm Merck Group, has filed for an $86.3m initial public offering. Founded in 2016, Vera is developing therapies for the treatment of immunological and inflammatory diseases. Its lead drug candidate, atacicept, blocks the production of antibodies that…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.